​
​

NLS Pharmaceutics Stock (NASDAQ:NLSP)

ForecastOwnershipFinancialsChart
NLS Pharmaceutics by TradingView

Previous Close

$0.13

52W Range

$0.11 - $1.01

50D Avg

$0.18

200D Avg

$0.28

Market Cap

$6.31M

Avg Vol (3M)

$11.96M

Beta

-0.57

Div Yield

-

NLSP Company Profile

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CH

Employees

6

IPO Date

Jan 29, 2021

Website

NLSP Performance

NLSP Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-11.81M$-15.48M$-11.86M
Net Income$-12.17M$-16.50M$-11.95M
EBITDA$-11.80M$-15.47M$-11.85M
Basic EPS$-0.32$-0.84$-0.81
Diluted EPS$-0.32$-0.84$-0.81

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
ACHLAchilles Therapeutics plc
LIXTLixte Biotechnology Holdings, Inc.
KTTAPasithea Therapeutics Corp.
ACRVAcrivon Therapeutics, Inc. Common Stock
CTMXCytomX Therapeutics, Inc.
QNRXQuoin Pharmaceuticals, Ltd.
HCWBHCW Biologics Inc.
ASMBAssembly Biosciences, Inc.
RZLTRezolute, Inc.
INDPIndaptus Therapeutics, Inc.
NRBONeuroBo Pharmaceuticals, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
PTIXProtagenic Therapeutics, Inc.
MOLNMolecular Partners AG
NLTXNeurogene Inc.
TILInstil Bio, Inc.
ELYMEliem Therapeutics, Inc.